Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
Pancreatic Adenocarcinoma With Strong Expression of Interleukin-13 Receptor α2 Shows a Poor Response to Gemcitabine-Based Chemotherapy.
复制标题
强表达白细胞介素 13 受体 α2 的胰腺腺癌对基于吉西他滨的化疗反应不佳。
DOI：
10.1097/mpa.0000000000002151
复制
发表时间：
2022
期刊：
影响因子：
2.9
通讯作者：
Isayama H.
中科院分区：
文献类型：
--
作者：
Tomishima K;Fujisawa T;Fukumura Y;Ushio M;Fukuma T;Takahashi S;Takasaki Y;Suzuki A;Ito K;Ishii S;Yao T;Nagahara A;Isayama H.
目的在小鼠原位胰腺癌模型中，IL-13受体α-2(IL-13Rα-2)高表达与预后不良和吉西他滨耐药有关。探讨IL-13Rα-2在经鼻内窥镜超声细针抽吸活检标本中表达的影响。方法选择经超声细针抽吸确诊的胰腺导管腺癌患者，接受吉西他滨化疗。采用免疫组织化学方法检测肿瘤组织中IL-13R、α-2的表达，并采用盲法进行肿瘤分级(阴性、弱、强)。结果95例患者中，IL-13Rα-2强表达组63例，弱/阴性组32例。IL-13Rα2强表达组的无进展生存率和总生存率明显低于弱/阴性组(P=0.0191和P=0.0062)。IL-13Rα-2强表达与治疗后3个月的进展相关(优势比为13.72，P=0.0143)。结论胰腺癌组织中IL-13Rα-2表达强，预后差，对G-CTX的疗效差。
ObjectivesPancreatic ductal adenocarcinoma with strong expression of interleukin-13 receptor α2 (IL-13Rα2) was associated with poor prognosis and gemcitabine resistance in an orthotopic mouse model. We evaluated the influence of IL-13Rα2 expression in the endoscopic ultrasound–fine needle aspiration (EUS-FNA) specimen.MethodsWe included patients with pancreatic ductal adenocarcinoma, as diagnosed by EUS-FNA, who received gemcitabine-based chemotherapy (G-CTX). Tumor expression of IL-13Rα2 was assessed by immunohistochemistry and classified using a three scale (negative, weak, or strong) in a blinded fashion. The effect of G-CTX was assessed by tumor reduction rate by computed tomography after 3 months.ResultsA total of 95 patients were enrolled, and 63 and 32 cases were determined with strong and weak/negative expression of IL-13Rα2. The IL-13Rα2–strong group showed significantly poorer progression-free and overall survival rates than weak/negative group (P= 0.0191 and P= 0.0062, respectively). Strong expression of IL-13Rα2 was associated with progression factor after 3 months of the first G-CTX (odds ratio, 13.72; P= 0.0143).ConclusionsPancreatic ductal adenocarcinoma with strong expression of IL-13Rα2 in EUS-FNA specimens showed poor prognosis and poor response to G-CTX.